Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)

3 months ago 67

Lee Samaha, The Motley Fool

Tue, July 7, 2026 astatine 11:52 AM CDT 3 min read

Shares successful Agios Pharmaceuticals (NASDAQ: AGIO) were higher by much than 14% arsenic of 11 a.m this morning. The determination comes aft a precise affirmative improvement from the Food and Drug Administration (FDA) connected its cardinal drug, mitapivat.

Agios and mitapivat

The institution already has mitapivat approved for adults with pyruvate kinase (PK) deficiency and for adults with alpha- oregon beta-thalassemia. However, it's besides seeking support for sickle compartment illness (SCD) based connected a Phase 3 proceedings completed past year. The bully quality is the proceedings met its superior endpoint of "hemoglobin effect and cardinal secondary endpoints of alteration from baseline successful hemoglobin attraction and indirect bilirubin."

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

However, it did not conscionable the superior endpoint of demonstrating a statistically important simplification successful sickle compartment symptom crises (SCPCs). Sickle cells tin physique up successful humor vessels, blocking humor travel and depriving organs of oxygen-rich blood, starring to acute pain.

What happened contiguous

Despite failing to conscionable the SCPCs endpoint, Agios is seeking support of mitapivat for SCD, and contiguous the FDA announced it had accepted Agios' supplemental New Drug Application (NDA) for mitapivat for SCD "with a Priority Review." Moreover, it acceptable a extremity day for a determination by Nov.1.

What it means for Agios Pharmaceuticals

This is simply a affirmative improvement that implies the FDA is sufficiently impressed by the information the pharmaceutical institution submitted that it's consenting to assistance it a faster review, contempt mitapivat missing the SCPCs-related endpoint.

To beryllium clear, though, this is for an accelerated approval. A afloat accepted support is contingent connected the REIGNITE Phase 3 Confirmatory Trial, which Agios is conducting nether the FDA's accelerated support pathway, and those results won't beryllium disposable until adjacent twelvemonth astatine the earliest. Still, today's quality is simply a nett positive, and investors are close to invited it.

Should you bargain banal successful Agios Pharmaceuticals close now?

Before you bargain banal in Agios Pharmaceuticals, see this:

The Motley Fool Stock Advisor analyst squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Agios Pharmaceuticals wasn't 1 of them. The 10 stocks that made the chopped are built for semipermanent maturation and could nutrient monster returns successful the coming years.

Read Entire Article